{"id":"https://openalex.org/W123737891","doi":null,"title":"[Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].","display_name":"[Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].","publication_year":1999,"publication_date":"1999-08-15","ids":{"openalex":"https://openalex.org/W123737891","mag":"123737891","pmid":"https://pubmed.ncbi.nlm.nih.gov/10479965"},"language":"de","primary_location":{"id":"pmid:10479965","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10479965","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Praxis","raw_type":"Case Reports"},"parent_works":[],"lineage":["https://openalex.org/W123737891"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032688667","display_name":"Andreas Otte","orcid":"https://orcid.org/0000-0002-6290-6786","observed_orcids":["https://orcid.org/0000-0002-6290-6786"]},"institutions":[{"id":"https://openalex.org/I2802542264","display_name":"University Hospital of Basel","ror":"https://ror.org/04k51q396","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I2802542264"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"A Otte","raw_affiliation_strings":["Klinik und Institut f\u00fcr Nuklearmedizin, Universit\u00e4tskliniken, Kantonsspital Basel. otte@ubaclu.unibas.ch"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Klinik und Institut f\u00fcr Nuklearmedizin, Universit\u00e4tskliniken, Kantonsspital Basel. otte@ubaclu.unibas.ch","institution_ids":["https://openalex.org/I2802542264"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108413503","display_name":"R. P. Herrmann","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R Herrmann","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083154878","display_name":"Helmut Robert M\u00e4cke","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H R M\u00e4cke","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5029698599","display_name":"Jan M\u00fcller\u2010Brand","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J M\u00fcller-Brand","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.3473,"has_fulltext":false,"cited_by_count":18,"citation_normalized_percentile":{"value":0.58036138,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":93},"biblio":{"volume":"88","issue":"31-32","first_page":"1263","last_page":"1268"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.9810000061988831,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.9810000061988831,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.017999999225139618,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12505","display_name":"Peptidase Inhibition and Analysis","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/somatostatin-analogs","display_name":"somatostatin analogues","score":0.921999990940094},{"id":"https://openalex.org/keywords/neuroendocrine-tumors","display_name":"neuroendocrine tumors","score":0.8629999756813049},{"id":"https://openalex.org/keywords/brachytherapy","display_name":"brachytherapy","score":0.796999990940094},{"id":"https://openalex.org/keywords/radiopharmaceuticals","display_name":"radiopharmaceuticals","score":0.8190000057220459},{"id":"https://openalex.org/keywords/somatostatin-receptors","display_name":"somatostatin receptors","score":0.8759999871253967},{"id":"https://openalex.org/keywords/peptide-receptor-radionuclide-therapy","display_name":"peptide receptor radionuclide therapy","score":0.7760000228881836},{"id":"https://openalex.org/keywords/nephrotoxicity","display_name":"nephrotoxicity","score":0.8450000286102295},{"id":"https://openalex.org/keywords/hematological-toxicity","display_name":"hematologic toxicity","score":0.9350000023841858},{"id":"https://openalex.org/keywords/tumor-response","display_name":"tumor response","score":0.6449999809265137}],"concepts":[{"id":"https://openalex.org/C2781025020","wikidata":"https://www.wikidata.org/wiki/Q419935","display_name":"Octreotide","level":3,"score":0.6821562051773071},{"id":"https://openalex.org/C2776297358","wikidata":"https://www.wikidata.org/wiki/Q407166","display_name":"Somatostatin","level":2,"score":0.6652891039848328},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6650960445404053},{"id":"https://openalex.org/C2779384505","wikidata":"https://www.wikidata.org/wiki/Q17007513","display_name":"Concomitant","level":2,"score":0.6488243341445923},{"id":"https://openalex.org/C80115893","wikidata":"https://www.wikidata.org/wiki/Q2067077","display_name":"Somatostatin receptor","level":3,"score":0.5743001103401184},{"id":"https://openalex.org/C509974204","wikidata":"https://www.wikidata.org/wiki/Q180507","display_name":"Radiation therapy","level":2,"score":0.5355411171913147},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.5271317958831787},{"id":"https://openalex.org/C2779066768","wikidata":"https://www.wikidata.org/wiki/Q1981276","display_name":"Neuroendocrine tumors","level":2,"score":0.4862886369228363},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.45906785130500793},{"id":"https://openalex.org/C2993559085","wikidata":"https://www.wikidata.org/wiki/Q2126444","display_name":"Radionuclide therapy","level":2,"score":0.45024585723876953},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.42983928322792053},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.41883015632629395},{"id":"https://openalex.org/C2989005","wikidata":"https://www.wikidata.org/wiki/Q214963","display_name":"Nuclear medicine","level":1,"score":0.3382214307785034},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3216784596443176}],"mesh":[{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010865","descriptor_name":"Pilot Projects","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011832","descriptor_name":"Radiation Injuries","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D011877","descriptor_name":"Radionuclide Imaging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011879","descriptor_name":"Radiotherapy Dosage","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015021","descriptor_name":"Yttrium Radioisotopes","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015021","descriptor_name":"Yttrium Radioisotopes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015282","descriptor_name":"Octreotide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015282","descriptor_name":"Octreotide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D015282","descriptor_name":"Octreotide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017481","descriptor_name":"Receptors, Somatostatin","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D018358","descriptor_name":"Neuroendocrine Tumors","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D018358","descriptor_name":"Neuroendocrine Tumors","qualifier_ui":"Q000532","qualifier_name":"radiotherapy","is_major_topic":true},{"descriptor_ui":"D018358","descriptor_name":"Neuroendocrine Tumors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false}],"locations_count":3,"locations":[{"id":"pmid:10479965","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10479965","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Praxis","raw_type":"Case Reports"},{"id":"pmh:oai:opus.hs-offenburg.de:12200","doi":null,"is_oa":false,"landing_page_url":"https://opus.hs-offenburg.de/frontdoor/index/index/docId/12200","pdf_url":null,"source":{"id":"https://openalex.org/S4377196587","display_name":"Opus-HSO (Offenburg University of Applied Sciences)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I913140155","host_organization_name":"Offenburg University of Applied Sciences","host_organization_lineage":["https://openalex.org/I913140155"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article"},{"id":"mag:123737891","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10479965","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9763000011444092,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2133962195","https://openalex.org/W2049643474","https://openalex.org/W4296766361","https://openalex.org/W2012600554","https://openalex.org/W1984882652","https://openalex.org/W2158985582","https://openalex.org/W2024035978","https://openalex.org/W2032009252","https://openalex.org/W2493726071"],"abstract_inverted_index":{"Current":[0],"concepts":[1,116],"for":[2,42],"the":[3,23,38,72,82,111],"treatment":[4],"of":[5,84,94,113],"somatostatin":[6],"receptor":[7],"positive":[8],"tumours":[9],"have":[10,51],"not":[11],"been":[12],"very":[13],"motivating":[14],"up":[15],"to":[16,65,78,107],"now.":[17],"A":[18],"promising":[19],"alternative":[20],"could":[21],"be":[22,35],"new":[24,57,73],"peptidic":[25],"vector":[26],"DOTA-D-Phe1-Tyr3-Octreotide":[27],"(DOTATOC)":[28],"recently":[29],"developed":[30],"in":[31,81,88,124],"Basel.":[32],"It":[33],"may":[34],"labelled":[36],"with":[37,55,63,117],"beta-emitter":[39],"yttrium-90":[40],"(90Y)":[41],"internal":[43],"radiotherapy":[44],"after":[45],"systemic":[46],"application.":[47],"Pilot":[48],"therapy":[49,76],"studies":[50,60],"shown":[52],"convincing":[53],"results":[54],"this":[56],"radiopharmaceutical.":[58],"These":[59],"are":[61,128],"presented":[62],"regard":[64],"efficacy":[66],"and":[67,86,103],"possible":[68],"toxicity.":[69],"In":[70],"summary,":[71],"receptor-mediated":[74],"90Y-DOTATOC":[75],"led":[77],"tumour":[79],"response":[80],"majority":[83],"patients,":[85],"only":[87],"some":[89],"receiving":[90],"high":[91],"cumulative":[92],"doses":[93],">":[95],"200":[96],"mCi":[97],"per":[98],"m2":[99],"body":[100],"surface":[101],"renal":[102,114],"hematological":[104],"toxicity":[105],"due":[106],"irradiation":[108],"occurred.":[109],"For":[110],"reduction":[112],"accretion,":[115],"concomitant":[118],"amino":[119],"acid":[120],"infusions":[121],"containing":[122],"L-lysine":[123],"a":[125],"higher":[126],"concentration":[127],"currently":[129],"under":[130],"way.":[131]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
